These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 37479945

  • 1. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
    Cao D, Deng C, Wang G, Mei X, Xie J, Liu Y, Liu Y, Yang Y, Li S, Liu C.
    Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
    [Abstract] [Full Text] [Related]

  • 2. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects.
    Wu X, Wynne C, Xu C, Gan Y, Wang C, Thomas BE, Yu JC, Li S, Zhang L.
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
    Chen L, Rangel JDG, Cil T, Li X, Cicin I, Shen Y, Liu Z, Ozyilkan O, Igor B, Chen J, Oleksandr K, Chen Z, Zhang H, Fu Z, Dong Q, Song S, Yu JC, Zhang L.
    Cancer Med; 2023 Nov; 12(22):20847-20863. PubMed ID: 37935428
    [Abstract] [Full Text] [Related]

  • 4. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
    Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, Liu J.
    MAbs; 2018 Nov; 10(4):678-691. PubMed ID: 29553864
    [Abstract] [Full Text] [Related]

  • 5. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
    Yu C, Zhang F, Xu G, Wu G, Wang W, Liu C, Fu Z, Li M, Guo S, Yu X, Wang L.
    Anal Chem; 2020 Feb 18; 92(4):3161-3170. PubMed ID: 31983199
    [Abstract] [Full Text] [Related]

  • 6. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
    Peraza MA, Rule KE, Shiue MHI, Finch GL, Thibault S, Brown PR, Clarke DW, Leach MW.
    Regul Toxicol Pharmacol; 2018 Jun 18; 95():236-243. PubMed ID: 29574193
    [Abstract] [Full Text] [Related]

  • 7. Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method.
    Kim H, Hong E, Lee J, Hong S, Kim J, Cho M, Kim Y, Yoo T.
    BioDrugs; 2023 Jul 18; 37(4):569-581. PubMed ID: 37060541
    [Abstract] [Full Text] [Related]

  • 8. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
    Lee JH, Paek K, Moon JH, Ham S, Song J, Kim S.
    BioDrugs; 2019 Aug 18; 33(4):411-422. PubMed ID: 31190280
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis® (Ranibizumab) Biosimilar.
    Kim E, Han J, Chae Y, Park H, Kim S, Kim S, Lee J, Kim BC.
    Ophthalmol Ther; 2022 Apr 18; 11(2):639-652. PubMed ID: 35084693
    [Abstract] [Full Text] [Related]

  • 10. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
    Lee KH, Lee J, Bae JS, Kim YJ, Kang HA, Kim SH, Lee SJ, Lim KJ, Lee JW, Jung SK, Chang SJ.
    MAbs; 2018 Apr 18; 10(3):380-396. PubMed ID: 29469653
    [Abstract] [Full Text] [Related]

  • 11. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
    Zhang L, Yu L, Xu Y, Qin P, Shen P, Liu K, Fei M, Wang H, Cao Y, Lu L, Gao W, Zhang Z.
    Anal Bioanal Chem; 2023 Jul 18; 415(17):3341-3362. PubMed ID: 37162525
    [Abstract] [Full Text] [Related]

  • 12. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I, Beydon ME, Solís C, Sacristán D, Vandenheede I, Ortiz A, Sandra K, Adhikary L.
    Biologicals; 2022 Jun 18; 77():1-15. PubMed ID: 35667958
    [Abstract] [Full Text] [Related]

  • 13. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL, Wang YL, Hu TM, Hsu LF.
    BioDrugs; 2019 Aug 18; 33(4):437-446. PubMed ID: 31111423
    [Abstract] [Full Text] [Related]

  • 14. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
    Xu Y, Xie L, Zhang E, Gao W, Wang L, Cao Y, Xie MH, Jiang W, Liu S.
    MAbs; 2019 Apr 18; 11(3):606-620. PubMed ID: 30794092
    [Abstract] [Full Text] [Related]

  • 15. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M.
    BioDrugs; 2013 Oct 18; 27(5):495-507. PubMed ID: 23649935
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
    Goyal P, Vats B, Subbarao M, Honnappa CG, Kabadi P, Rohil S, Bera A, Mehta GR, Pai H, Adhikari L, Tagore R, Sharma S, Venkatachala R, Nair P, Annegowda S, Sahu A, Trivedi S, Shastri N, Gokhale Y, Thomas R, Thakur A, Mohan D, Rao K U, Melarkode R, Ullanat R.
    Expert Opin Biol Ther; 2022 Feb 18; 22(2):271-298. PubMed ID: 34465264
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH, Lee N, Song D, Jung SY, Bou-Assaf G, Sosic Z, Zhang W, Lyubarskaya Y.
    MAbs; 2016 Feb 18; 8(6):1136-55. PubMed ID: 27246928
    [Abstract] [Full Text] [Related]

  • 20. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH, Han S, Ghim JL, Nam MS, Yu S, Park T, Kim S, Bae J, Shin JG.
    BioDrugs; 2019 Apr 18; 33(2):173-181. PubMed ID: 30850957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.